ArticlePloS one2025
Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOpioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race/ethnicity on this association.
objectiveTo assess the impact of race and ethnicity on the association between psilocybin use and lowered odds of OUD using data from the National Survey on Drug Use and Health (2002-2019) (N = 706,891).
methodI used survey-weighted multivariable logistic regression to test whether race/ethnicity moderates the association between psilocybin use and lowered odds of OUD. Subsequently, I stratified my sample by race and ethnicity and assessed the associations between psilocybin and OUD for individual racial and ethnic groups (White, Black, Indigenous, Asian, Multiracial, Hispanic). My analysis plan was pre-registered.
resultsRace and ethnicity significantly moderated the association between psilocybin and OUD. Furthermore, when I stratified my sample by race and ethnicity, only White participants and Hispanic participants demonstrated a link between psilocybin and lowered odds of OUD (White aOR: 0.84; Hispanic aOR: 0.68). For Black, Asian, Indigenous, and Multiracial participants, psilocybin did not share a significant association with OUD.
conclusionRace and ethnicity moderate the associations between psilocybin and OUD. Future longitudinal, experimental, and qualitative research is needed to better understand the pattern of associations I observed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.